

UC San Diego

UC San Diego Previously Published Works

Title

Enteral tranexamic acid attenuates vasopressor resistance and changes in α 1-adrenergic receptor expression in hemorrhagic shock

Permalink

<https://escholarship.org/uc/item/6j49x120>

Journal

Journal of Trauma and Acute Care Surgery, 83(2)

ISSN

2163-0755

Authors

Santamaria, Marco Henry
Aletti, Federico
Li, Joyce B
[et al.](#)

Publication Date

2017-08-01

DOI

10.1097/ta.0000000000001513

Peer reviewed

Journal of Trauma and Acute Care Surgery

Enteral tranexamic acid attenuates vasopressor resistance and changes in α 1-adrenergic receptor expression in hemorrhagic shock

--Manuscript Draft--

Manuscript Number:	JT-D-16-06042R1
Full Title:	Enteral tranexamic acid attenuates vasopressor resistance and changes in α 1-adrenergic receptor expression in hemorrhagic shock
Article Type:	Original Article
Section/Category:	
Keywords:	Hemorrhagic shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic receptor
Corresponding Author:	Federico Aletti, Ph.D. Politecnico di Milano Milan, MI ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Politecnico di Milano
Corresponding Author's Secondary Institution:	
First Author:	Marco Santamaria, M.Sc.
First Author Secondary Information:	
Order of Authors:	Marco Santamaria, M.Sc. Federico Aletti, Ph.D. Joyce B Li Aaron Tan Monica Chang Jessica Leon Geert W Schmid-Schönbein, Ph.D. Erik B Kistler, M.D., Ph.D.
Order of Authors Secondary Information:	
Manuscript Region of Origin:	UNITED STATES

Enteral tranexamic acid attenuates vasopressor resistance and changes in α_1 -adrenergic receptor expression in hemorrhagic shock

*Marco Santamaria¹, *Federico Aletti^{2,1}, Joyce B. Li¹, Aaron Tan¹, Monica Chang¹, Jessica Leon¹, Geert W. Schmid-Schönbein¹ and Erik B. Kistler³

¹ Department of Bioengineering, University of California San Diego, San Diego, CA, U.S.A.

² Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy

³Department of Anesthesiology & Critical Care, VA San Diego Healthcare System

Running Head: α_1 receptor changes in hemorrhagic shock

Keywords: Hemorrhagic Shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic receptor.

Corresponding Author:

Federico Aletti, PhD

Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano

Piazza Leonardo da Vinci, 32 – 20133 – Milan, Italy.

E-mail address: federico.aletti@polimi.it

*These authors contributed equally to the work as co-first authors.

ABSTRACT

BACKGROUND: Irreversible hemorrhagic shock is characterized by hyporesponsiveness to vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to this phenomenon. Previous studies have shown that decreased intestinal perfusion in hemorrhagic shock leads to proteolytically-mediated increases in gut permeability, with subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is achieved in part by α_1 receptor modulation, which may be affected by vasoactive factors; we thus hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be prevented by enteral protease inhibition. **METHODS:** Rats were exposed to experimental hemorrhagic shock (35 mmHg mean arterial blood pressure for 2 hrs, followed by reperfusion for 2 hrs) and challenged with phenylephrine (2 $\mu\text{g}/\text{kg}$) at discrete intervals to measure vasopressor responsiveness. A second group of animals received enteral injections with the protease inhibitor tranexamic acid (TXA) (127 mM) along the small intestine and cecum one hour following induction of hemorrhagic shock.

RESULTS: Blood pressure response (duration and amplitude) to phenylephrine after reperfusion was significantly attenuated in animals subjected to hemorrhagic shock compared to baseline and control non-shocked animals, and was restored to near baseline by enteral TXA. Arteries from shocked animals also displayed decreased α_1 receptor density with restoration to baseline following enteral TXA treatment. In vitro, rat shock plasma decreased α_1 receptor density in smooth muscle cells, which was also abrogated by enteral TXA treatment.

CONCLUSIONS: Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the α_1 -selective agonist phenylephrine and decreased α_1 receptor density via circulating shock factors. These changes are mitigated by enteral TXA with

correspondingly improved hemodynamics. Proteolytic inhibition in the lumen of the small intestine improves **hemodynamics** in hemorrhagic shock, possibly by restoring α_1 adrenergic functionality necessary to maintain systemic blood pressure and perfusion.

LEVEL OF EVIDENCE: N/A

Acknowledgement: Supported by NIH grant GM 85072, Career Development Award (CDA2) 1IK2BX001277-01A1 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, GM 85072, the “CelSys Shock” Marie Curie International Outgoing Fellowship (PIOF-GA-2012-328796) of the European Union in support of the corresponding author, and the “ShockOmics” Project of the European Union (Grant#602706).

BACKGROUND

One of the most challenging problems in the care of patients suffering from circulatory shock is vasopressor resistance, which is characterized by hyporesponsiveness to the infusion of vasoactive drugs required to maintain adequate hemodynamics. The mortality of patients in shock requiring vasopressors is high (> 50%) and hypotension characterizes the majority of deaths despite vasopressor support.¹⁻³

While the cause of hypotension that typically accompanies and characterizes circulatory shock can be attributed to vasodilation generated by the strong inflammatory response occurring in shock, no consensus exists as to the mechanisms for vasopressor hyporeactivity. Several hypotheses have been postulated to account for vasopressor resistance. For instance, it is known that systemic vasopressin levels are reduced in shock⁴ and that nitric oxide production may be increased and contributes to vasodilation and cardiac dysfunction.⁵ However, clinical trials have proposed therapies interfering with these pathways without success in reducing mortality to vasopressor resistance-induced refractory shock.^{6,7}

One potential mechanism contributing to hyporesponsiveness to vasopressor administration in hemorrhagic shock may be altered function of the vascular α_1 adrenergic receptor, a G_q -coupled receptor which is a fundamental controller of vascular tone and determinant of systemic vascular resistance (SVR). Activation of α_1 increases intracellular calcium and subsequent smooth muscle contraction resulting in vasoconstriction of the vasculature. Although the α_1 adrenergic receptor is also found in the heart, α_1 appears to be almost exclusively involved in the maintenance of vascular tone.^{8,9} SVR and thus blood pressure, when exogenously supported in the critical care setting, are with the exception of

vasopressin, controlled by agents that act on the α_1 adrenergic receptor (phenylephrine, epinephrine, norepinephrine, dopamine). Therefore, decreased responsiveness to this receptor has important implications for available treatment options and outcome.

It has been previously shown that hemorrhagic shock may reduce the surface density of important transmembrane receptors, such as the insulin receptor,¹⁰ thus reducing the response to insulin (insulin resistance) in shock. We hypothesize that decreased transmembrane receptor density in shock may result, either directly or indirectly, from uncontrolled proteolytic activity, possibly by digestive pancreatic enzymes from the small intestine.¹¹ Integrity of the intestinal mucous layer is compromised in circulatory shock,¹²⁻¹⁴ and a consequence of the breakdown of this barrier may be leakage of digestive enzymes and inflammatory products from the intestinal lumen into the bloodstream.¹⁵ Once in the systemic circulation, these mediators may lead to remote organ failure and mortality (autodigestion).¹¹

The objective of this study was to investigate a new hypothesis for vasopressor resistance in shock, by analyzing alterations in α_1 adrenergic receptor expression in a rat model of hemorrhagic shock. We also tested a therapeutic intervention aimed at maintaining vasopressor responsiveness in hemorrhagic shock, by the administration of tranexamic acid (TXA) in the intestinal lumen. Used intravenously to decrease bleeding predominantly due to its actions as a plasminogen inhibitor,¹⁶ TXA also can function as a trypsin inhibitor and has been shown to improve outcomes in shock when given enterally,¹⁵ in part by protecting the gut mucosal barrier from proteolytic degradation.^{17, 18}

METHODS

A. Experimental Protocol

All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego and conform to the Guide for the Care and Use of Laboratory Animals, 8th edition, by the National Institutes of Health (2011). Twenty-four non-fasted male Wistar rats (300-450 g, Harlan Laboratories, Inc., Indianapolis, IN) were randomly assigned to either Control (no shock) (n=6), hemorrhagic shock (HS) (n=6), hemorrhagic shock with enteral tranexamic acid treatment (HS + TXA) (n=6), or hemorrhagic shock with enteral Golytely® (HS + Vehicle) as a hemorrhagic shock control (n=6). All rats were anesthetized (xylazine, 4 mg/kg; ketamine 75 mg/kg IM) with supplemental anesthesia administered intravenously as needed (xylazine, 4 mg/kg; ketamine 7.5 mg/kg IV). The right femoral vein and artery were cannulated for blood withdrawal and intravenous supplemental anesthesia and continuous monitoring of arterial pressure, respectively. Body temperature was maintained at 37°C via water-heated support and heat blanket.

Control animals were monitored for 4 hours under anesthesia without other interventions. HS and HS + TXA animals were allowed 5 min for hemodynamic stabilization after induction of anesthesia and vascular line placement. All animals were heparinized (1 unit heparin/cc total blood volume, estimated at 6% body weight, intravenously) to allow for blood withdrawal. Hemorrhage was induced by blood withdrawal through the femoral vein (0.5 cc/min) to a target mean arterial blood pressure (MABP) of 35 mmHg. MABP was maintained between 30 and 40 mmHg for 2 hours, after which time the withdrawn blood was returned to the animals (0.5 cc/min). Maintenance of MABP during the ischemic period was accomplished by the removal or

return of small aliquots of blood as necessary to ensure maintenance of the targeted pressure. The shed blood was maintained at room temperature (22°C) during hypovolemia, and warmed to 37°C prior to return to the animals. Animals were monitored for an additional two hours upon completion of blood return.

To test for vascular responsiveness the selective α_1 adrenergic agonist phenylephrine (2 $\mu\text{g}/\text{kg}$) was administered as intravenous bolus (0.1 ml) once before hemorrhage to obtain baseline response and again serially at 30 minutes, 90 minutes, and 120 minutes after the start of reperfusion. Total deflection of MABP from baseline (ΔMABP), i.e. difference between maximum value of MABP after challenge and value before challenge, as well as duration of response (DOR) (time to return to within 3% of baseline) were measured as indices of vascular response to phenylephrine. In addition, % changes in the area-under-the-curve (ΔAUC) from baseline were calculated for all animals and all groups as another method for understanding and interpreting the data.

In HS + TXA animals, tranexamic acid (127 mM TXA, Cyclokapron, Pfizer) was administered at 1 hour into the hypovolemic period into the lumen of the small intestine via sequential injections (BD Sub-Q 26G 5/8 PrecisionGlide Needle, Becton Dickinson & Co.) spaced approximately 5 cm apart for an average of 8 injections longitudinally along its length. GoLyteLy® (0.14 g /ml 0.9% sterile water) was used as carrier solution. A total fluid volume of 15 ml was injected into the lumen of the small intestine. An additional 2 ml of TXA in vehicle was injected into the cecum. The dosage of the TXA was based on previously determined effective concentrations.¹⁵ A second group of animals (HS + Vehicle) undergoing hemorrhagic shock was instrumented as above and enteral injections of carrier solution only (GoLyteLy®) were performed as an additional hemorrhagic shock control. Hemodynamics from this group

were indistinguishable from those of the HS group, and subsequent analyses were carried out on the HS animals (**Figure 1**). HS, HS + TXA, and HS + Vehicle groups were subjected to phenylephrine challenge (2 $\mu\text{g}/\text{kg}$) as described above once before hemorrhage and at 30, 90, and 120 min after the start of the reperfusion period.

Following a two-hour observation period after return of shed blood (Reperfusion), animals were euthanized with B-Euthanasia (120 mg/kg). Death was confirmed by loss of signal on blood pressure monitor followed by bilateral thoracotomy.

B. Tissue Collection

Renal arteries were harvested following laparotomy, gently rinsed to remove residual blood and homogenized in lysis buffer (ThermoScientific). Homogenates were treated with the addition of a protease inhibitor cocktail (1:25, Roche) for Western blot analysis. Arterial homogenates were stored at -80°C for later use. Right femoral arteries were gently excised, washed four times in 10% formalin for 15 min each, and placed directly into 10% formalin and stored at room temperature for immunohistochemical analysis (IHC).

C. Western Blot Detection of Arterial α_1 Adrenergic Receptor

Renal artery homogenate samples from each animal (60 $\mu\text{l}/\text{sample}$; 0.5 $\mu\text{g}/\mu\text{l}$) were separated by SDS-PAGE. For Western blotting, proteins were transferred to a 0.45 μm pore size nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA; #162-0097). Following blockade with 5% nonfat dry milk in buffer (Tris-Buffered Saline and Tween 20, TBST),

primary antibodies against α_{1D} adrenergic receptor (α_{1R}) (H-142, 1:300, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) were applied. β -actin (C4, 1:100, sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA) was used as loading control. Corresponding secondary antibodies were applied at 1:5000 dilution. Antibodies were diluted in TBST. Supersignal West Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA; #34096) was used for imaging. Molecular weights were estimated by use of an electrophoresis marker (Sigma Aldrich, C1992). Gels were digitized and bands were analyzed by densitometry in ImageJ, and results are reported as ratios of α_{1R} / β -actin.

D. Immunohistochemistry (IHC) Detection of Arterial α_1 Adrenergic Receptor

Femoral arteries were resected, formalin fixed, and mounted longitudinally for sectioning. 30 μ m sections were made along the length of the artery and placed in 10% formalin overnight. Sections were rinsed in distilled water to remove residual formalin. Endogenous peroxidase activity was removed with Bloxall (Vector Laboratories, Burlingame, CA, SP-6000). 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, S-2012) was then used as a blocking reagent followed by primary antibody incubation with α_{1D} antibody (1:200, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) for 90 min. Sections were incubated for 30 min in ImmPRESS anti-rabbit Ig (Vector Laboratories, Burlingame, CA, MP-7401) and ImmPACT DAB (Vector Laboratories, Burlingame, CA, SK-4105) was used for staining. Sections were mounted using Vectamount (Vector Laboratories, Burlingame, CA, H-5000). Bright-field imaging was carried out at 10X objective magnification. Images were digitized to 8-bit format and measurements were taken of smooth muscle regions in each section (6 measurements/image,

10 images/animal). All analysis was performed on ImageJ. Precautions were taken to assure that all IHC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

E. Immunocytochemistry of Smooth Muscle Cells Following Rat Plasma Incubation (ICC)

Blood samples from Control (n = 6), HS (n = 6), HS + TXA (n = 6), and HS + Vehicle (n = 6) rats were drawn and blood was centrifuged at 600g for 10 min to achieve plasma separation. Human carotid smooth muscle cells (SMC) (HCtASMC; Cell Applications, San Diego, CA) were cultured in growth medium (311D-250; Cell Applications, San Diego, CA) at 37 °C in an atmosphere of 5% CO₂ and allowed to reach approximately 100% confluence before being exposed to either starvation medium (310-500; Cell Applications, San Diego, CA), or plasma from Control, HS, HS +TXA, or HS + Vehicle animals. SMCs were incubated in the presence of plasma variant or starvation medium for 3 hours at 37°C. Cells were starved in serum free media for 12 h prior to experimentation and plasma samples were diluted in a 1:5 ratio in starvation medium immediately prior to incubation. **Added plasma was normalized to volume rather than protein content.** Cells were stained as described above for rat femoral artery sections. Images were acquired at 10X objective magnification, digitized to 8-bit format and measurements were taken as the average intensity for individual cells. All analysis was performed on ImageJ. Precautions were taken to assure that all ICC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

F. Statistical Analysis

Data are presented as mean \pm standard deviation (SD) unless otherwise noted. One-way analysis of variance (ANOVA) was used where appropriate to evaluate the differences between groups with a post-hoc Tukey correction. All analyses were performed using Graphpad (Graphpad Software Inc., La Jolla, CA). A value of $p < 0.05$ was considered statistically significant for all tests.

RESULTS

A. Blood Pressure Response to Enteral TXA Treatment

All groups subjected to HS were maintained at similar systemic blood pressures during hypovolemia. After return of the shed blood, pressure was transiently restored, before dropping significantly in the HS and HS + Vehicle groups (**Figure 1**). The animal group treated enterally with TXA (HS + TXA) displayed significantly higher MABP after reperfusion compared to both shock groups.

B. Systemic Vasopressor Response

Vasopressor responsiveness to phenylephrine challenge *in vivo* during hemorrhagic shock was assessed by Δ MABP and DOR at baseline, and 30, 90 and 120 minutes after the start of reperfusion (**Figure 2**). There were no significant differences between groups for either Δ MABP or DOR at baseline. At 30 minutes after reperfusion there was a significant decrease in DOR for the HS + Vehicle group ($p < 0.01$) and Δ MABP for both HS and HS + Vehicle groups compared to baseline ($p < 0.01$, 0.0001, respectively) (**Figures 3 and 4**). This decrement in function in the untreated HS groups continued for the duration of the experiment in both HS and HS + Vehicle

groups (90 min: Δ MABP ($p < 0.001, 0.01$ respectively), DOR ($p < 0.05$), and 120 min: Δ MABP ($p < 0.05, 0.01$ respectively), and DOR ($p < 0.01$)). At no time point during the study did Δ MABP or DOR in the HS + TXA group differ significantly from baseline. Differences in the changes in the AUC (Δ AUC) from baseline (100%) showed a trend towards significance between the HS + Vehicle (26%, $p = 0.05$) and HS groups (37%, $p = 0.064$) vs. HS + TXA (71% of baseline response) at 90 minutes with significant differences between groups at 120 minutes: HS + Vehicle (23%) and HS (26%) vs. HS + TXA (71%, $p < 0.01$ for both groups).

C. α_1 Adrenergic Receptor Levels

The α_1 adrenergic receptor was examined by Western blot to determine whether there were changes in α_1 receptor density in shock and whether these levels were preserved after treatment with enteral TXA. α_1 receptor density was markedly decreased ($p < 0.01$) by HS as measured by Western blot (**Figure 5 A**) but maintained near Control levels by enteral treatment with TXA. Measurements of α_1 receptor density were confirmed using IHC combined with digital image analysis (**Figure 5 C**), where receptor levels as detected by immunolabeling were also significantly decreased in HS compared to Control ($p < 0.01$). Enteral treatment with TXA resulted in light absorbance levels similar to those of the Control group.

D. Human Carotid SMC α_1 Adrenergic Receptor Levels

SMCs were examined for α_1 using ICC (**Figure 6**). α_1 receptor density was significantly decreased in HS and HS + Vehicle compared to Control groups ($p < 0.001, p < 0.05$, respectively), while incubation with plasma from the HS + TXA group resulted in levels similar

to Control. α_1 receptor levels from the HS + Vehicle and HS groups did not differ significantly from each other.

DISCUSSION

Fulminate decompensated hemorrhagic shock (Class IV),¹⁹ characterized by limited responsiveness to fluid bolus and vasopressor therapy, carries a poor prognosis, in part because no effective interventions exist. Lack of responsiveness to vasopressors and failure to maintain vascular tone, commonly described in septic shock, are not well documented for hemorrhagic shock, and although several hypotheses have been proposed, there currently exists no consensus as to mechanism.²⁰ To study this problem, we examined the role of the α_1 adrenergic receptor in experimental hemorrhagic shock. The α_1 receptor is the archetypical adrenergic receptor most responsible for maintaining systemic vascular tone (vasoconstriction) and we hypothesized that failure of this receptor, either through reduced density or function, results in decreased vascular tone and subsequent hemodynamic collapse in hemorrhagic shock.⁸ Furthermore, we hypothesized that enteral treatment with tranexamic acid (TXA), a mild trypsin inhibitor,²¹ would lead to improved hemodynamics in hemorrhagic shock, in part by maintaining α_1 receptor activity by prevention of proteolytically-mediated processes. The mechanisms of action by which enteral TXA is effective in experimental hemorrhagic shock appears unrelated to TXA's well-known clinical role as an antifibrinolytic. Although IV TXA has some efficacy in hemorrhagic shock,¹⁶ this has not been consistently reported.²² Other protease inhibitors with differing effects on the coagulation system have also been found to be effective when given enterally to treat experimental shock,^{23,24} and the limited patient information on the subject appears to support the

hypothesis that the protease inhibitors must be given enterally to display marked clinical improvement.²⁵

This study confirms previous reports that enteral inhibition with TXA leads to improved hemodynamics in experimental hemorrhagic shock.¹⁵ Using phenylephrine as a probe for α_1 adrenergic receptor responsiveness, we report here that systemic sensitivity to this receptor decreases in experimental hemorrhagic shock with concomitant decrements in systemic pressure maintenance. The decrease in hemodynamic response is manifest as **measured by attenuated changes** in mean systemic blood pressure (Δ MABP) and in the duration of response (**DOR**) to the pressor agent phenylephrine, **as well as by changes in the total hemodynamic effectiveness of phenylephrine (Δ AUC)**. This reduction in hemodynamic responsiveness begins early in the reperfusion period and continues unabated through the end of the experiment. Western blot analysis and IHC confirm decreased α_1 adrenergic receptor density in hemorrhagic shock; the decrement in density appears to be a mechanism by which α_1 receptor-mediated hyporesponsiveness is mediated. This result is consistent with reports from other investigators on adrenergic function in shock, which appears to be predominantly related to changes in receptor density rather than function.²⁶

The mechanisms by which vascular α_1 adrenergic receptor density is modulated in shock are unknown, but results from our study demonstrate that circulating factors in the blood may be operant. These circulating mediators may include digestive pancreatic proteases¹⁵ and products of proteolysis that either directly,²⁷ or indirectly through vasoactive degradation products¹⁴ affect receptor function, and thus vascular responsiveness. Supporting this hypothesis are our current findings that enteral TXA restores receptor levels to baseline concentrations with commensurate improvements in hemodynamics in experimental hemorrhagic shock by protecting the ischemic

small bowel from proteolytic degradation;^{11, 12, 15} this protection is not seen with intravenous protease inhibitor treatment.²⁸

There are several limitations to this study. Among these is the lack of a detailed described mechanism by which enteral TXA inhibition in the bowel restores α_1 receptor function systemically. Previous studies have demonstrated increased survival after experimental shock with enteral protease inhibition,¹⁵ but not with intravenous protease inhibition.^{28, 29} The reasons for this are two-fold: first, the high concentrations of proteolytic enzymes in the bowel (millimolar range) can only be overcome by high concentrations of inhibitor in the bowel lumen, which is not feasible in the systemic circulation. Second, and more importantly, by limiting proteolytic degradation of the bowel mucosa and resulting permeability changes,^{13, 17, 18, 30} enteral protease inhibition prevents the systemic egress of non-protease gut mediators that might otherwise affect α_1 receptor function and result in subsequent hypotension. Further studies are necessary to identify the mediators and mechanisms responsible for this phenomenon. Likewise, although changes in α_1 receptor responsiveness appear to be secondary to changes in density as shown by Western blot and IHC analysis, the possibility of abnormal α_1 receptor binding or malfunction in hemorrhagic shock cannot be excluded. Finally, it is acknowledged that other receptors, both adrenergic (e.g., β_1 , β_2) and otherwise (e.g., vasopressin), are also operant and may be affected in hemorrhagic shock; further studies are necessary to clarify the roles of these receptors in this condition and the possible effect of enteral TXA in modulating them.

In conclusion, this study proposes a possible mechanism for vasopressor resistance-induced refractory shock by demonstrating that hemorrhagic shock decreases α_1 adrenergic receptor responsiveness and density. Decrements in α_1 adrenergic receptor activity and concentrations are mitigated by enteral treatment with TXA, with resultant improved

hemodynamics and vascular responsiveness. Restoration of α_1 receptor density and functionality may be a key mechanism by which enteral TXA improves systemic blood pressure and survival in experimental hemorrhagic shock.

AUTHOR CONTRIBUTION STATEMENT

MS, FA, JBL, AT, MC, and JL participated in data acquisition, analysis and experimental design; FA, GWS and EBK participated in experimental design, data analysis, data interpretation and drafting of the manuscript.

REFERENCES

1. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. *Crit Care Res Pract.* 2013;2013:654708
2. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. *The New England journal of medicine.* 2010;362:779-789
3. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F. Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. *Intensive Care Med.* 2010;36:2019-2029
4. Landry DW, Levin HR, Gallant EM, Ashton RC, Jr., Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation.* 1997;95:1122-1125
5. Thiemeermann C, Szabo C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. *Proceedings of the National Academy of Sciences of the United States of America.* 1993;90:267-271
6. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The triumph randomized controlled trial. *Jama.* 2007;297:1657-1666
7. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled,

- double-blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock. *Critical care medicine*. 2004;32:21-30
8. Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: Basic science and clinical implications. *Pharmacol Ther*. 2000;88:281-309
 9. Thiele RH, Nemergut EC, Lynch C, 3rd. The clinical implications of isolated alpha(1) adrenergic stimulation. *Anesth Analg*. 2011;113:297-304
 10. DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage: Mechanism for insulin resistance in the spontaneously hypertensive rat. *Hypertension*. 2008;52:415-423
 11. Altshuler AE, Kistler EB, Schmid-Schonbein GW. Autodigestion: Proteolytic degradation and multiple organ failure in shock. *Shock*. 2016;45:483-489
 12. Kistler EB, Alsaigh T, Chang M, Schmid-Schonbein GW. Impaired small-bowel barrier integrity in the presence of luminal pancreatic digestive enzymes leads to circulatory shock. *Shock*. 2012;38:262-267
 13. Chang M, Alsaigh T, Kistler EB, Schmid-Schonbein GW. Breakdown of mucin as barrier to digestive enzymes in the ischemic rat small intestine. *PLoS One*. 2012;7:e40087
 14. Alsaigh T, Chang M, Richter M, Mazor R, Kistler EB. In vivo analysis of intestinal permeability following hemorrhagic shock. *World J Crit Care Med*. 2015;4:287-295
 15. DeLano FA, Hoyt DB, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock. *Sci Transl Med*. 2013;5:169ra111
 16. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H,

- Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Oildashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (crash-2): A randomised, placebo-controlled trial. *Lancet*. 2010;376:23-32
17. Peng Z, Ban K, LeBlanc A, Kozar RA. Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. *J Trauma Acute Care Surg*. 2016;81:358-365
 18. Diebel ME, Diebel LN, Manke CW, Liberati DM, Whittaker JR. Early tranexamic acid administration: A protective effect on gut barrier function following ischemia/reperfusion injury. *J Trauma Acute Care Surg*. 2015;79:1015-1022
 19. Choi SB, Choi JY, Park JS, Kim DW. Atls hypovolemic shock classification by prediction of blood loss in rats using regression models. *Shock*. 2016
 20. Duan C, Yang G, Li T, Liu L. Advances in vascular hyporeactivity after shock: The mechanisms and managements. *Shock*. 2015;44:524-534
 21. Altshuler AE, Lamadrid I, Li D, Ma SR, Kurre L, Schmid-Schonbein GW, Penn AH. Transmural intestinal wall permeability in severe ischemia after enteral protease inhibition. *PLoS One*. 2014;9:e96655
 22. Sondeen JL, Hanson MA, Prince MD, de Guzman R, Polykratis IA, Aden JK, 3rd, Cap AP, Dubick MA. Double-blinded, placebo-controlled study of early tranexamic acid treatment in swine uncontrolled hemorrhage model. *J Trauma Acute Care Surg*. 2016;80:81-88

23. Doucet JJ, Hoyt DB, Coimbra R, Schmid-Schonbein GW, Junger WG, Paul LW, Loomis WH, Hugli TE. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock. *J Trauma*. 2004;56:501-510; discussion 510-501
24. Fitzal F, DeLano FA, Young C, Rosario HS, Schmid-Schonbein GW. Pancreatic protease inhibition during shock attenuates cell activation and peripheral inflammation. *J Vasc Res*. 2002;39:320-329
25. Lee YT, Wei J, Chuang YC, Chang CY, Chen IC, Weng CF, Schmid-Schonbein GW. Successful treatment with continuous enteral protease inhibitor in a patient with severe septic shock. *Transplant Proc*. 2012;44:817-819
26. Mizumachi K, Yahagi M, Kawabata H, Tezuka S, Honda T, Okada K. Decreased beta-adrenergic receptor density in rat myocardium during hemorrhagic shock. *J Anesth*. 1991;5:404-411
27. DeLano FA, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the small intestine prevents insulin resistance in hemorrhagic shock. *Shock*. 2014;41:55-61
28. Kistler EB, Lefer AM, Hugli TE, Schmid-Schonbein GW. Plasma activation during splanchnic arterial occlusion shock. *Shock*. 2000;14:30-34
29. Deitch EA, Shi HP, Lu Q, Feketeova E, Xu DZ. Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. *Shock*. 2003;19:452-456
30. Chang M, Kistler EB, Schmid-Schonbein GW. Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall. *Shock*. 2012;37:297-305

FIGURE LEGENDS

Figure 1

Mean arterial blood pressure (MABP) of Control, Hemorrhagic Shock (HS), Hemorrhagic Shock + Enteral Tranexamic Acid (HS + TXA), and Hemorrhagic Shock + Vehicle (HS + Vehicle) groups. MABP was decreased to a mean of 35 mmHg over several minutes by the serial withdrawal of small aliquots of blood (0.5 ml/min). Reperfusion was carried out in analogous fashion by slow reinfusion of shed blood (0.5 ml/min). ** $p < 0.01$ Control vs. HS + TXA and # $p < 0.0001$ HS, HS + Vehicle vs. HS + TXA and Control; # $p < 0.0001$ Control vs. HS, HS + Vehicle, HS + TXA during ischemia period as per experimental design. There were no statistical differences between HS and HS + Vehicle groups at any time points. Results shown as Mean \pm SD.

Figure 2

Representative hemodynamic response to phenylephrine challenge (Δ MABP) at 120 min after start of reperfusion for a single animal in each group.

Figure 3

(A) Average absolute change in MABP (Δ MABP) per group over time in response to phenylephrine challenge (Mean \pm SD). (B) Δ MABP response to phenylephrine challenge 30 min after start of reperfusion, (C) Δ MABP response to phenylephrine challenge 90 min after start of reperfusion, (D) Δ MABP response to phenylephrine challenge 120 min after start of reperfusion. * $p < 0.05$ Control vs. HS, ** $p < 0.01$ Control vs. HS, HS + Vehicle, *** $p < 0.001$ Control vs. HS, **** $p < 0.0001$ Control vs HS + Vehicle. Results plotted as Mean \pm SD.

Figure 4

(A) Average response duration to phenylephrine challenge (DOR) per group over time (Mean \pm SD). (B) DOR to phenylephrine challenge 30 min after start of reperfusion, (C) DOR to phenylephrine challenge 90 min after start of reperfusion, (D) DOR to phenylephrine challenge 120 min after start of reperfusion. * $p < 0.05$ Control vs. HS, HS + Vehicle, ** $p < 0.01$ Control vs. HS, HS + Vehicle. Results plotted as Mean \pm SD.

Figure 5

(A) α_{1D} renal artery band density by Western blot with representative α_{1D} renal artery band (α -1 AR). The average of the control band densities was used as a reference. β -actin is shown as a loading control for the same animals. (B) Histogram of the average relative band intensities per

group expressed as ratios of α_1R/β -actin (n=6 animals/group). *p < 0.05, HS vs. HS + TXA; **p < 0.01, Control vs. HS. Results plotted as Mean \pm SD. (C) Representative femoral artery sections labeled for α_{1D} . Insets indicate sample smooth muscle regions of interest (squared boxes) both before and after 8-bit conversion. (D) Histogram of labeling density values in digital units. Scale bar is = 100 microns. **p < 0.01 Control vs. HS, *p<0.05 HS + TXA vs all other groups. Results plotted as Mean \pm SD.

Figure 6

(A) Human carotid SMCs labeled for α_{1D} adrenergic receptor following 3 hour incubation with rat plasma, normalized with respect to added plasma volume. Histograms display labeling density values in digital units. Scale bar is = 10 microns. *p<0.05 Control vs. HS + Vehicle, ***p < 0.001 Control vs. HS, ***p<0.001 HS + TXA vs. HS + Vehicle, ****p<0.0001 HS + TXA vs. HS. Results plotted as Mean \pm SD.

1
2
3
4 **Enteral tranexamic acid attenuates vasopressor resistance and changes in α_1 -adrenergic**
5
6 **receptor expression in hemorrhagic shock**
7

8
9
10 *Marco Santamaria¹, *Federico Aletti^{2,1}, Joyce B. Li¹, Aaron Tan¹, Monica Chang¹, Jessica
11 Leon¹, Geert W. Schmid-Schönbein¹ and Erik B. Kistler³
12
13

14
15 ¹ Department of Bioengineering, University of California San Diego, San Diego, CA, U.S.A.
16
17

18 ² Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy
19
20

21 ³Department of Anesthesiology & Critical Care, VA San Diego Healthcare System
22
23
24
25
26
27
28
29
30

31 Running Head: α_1 receptor changes in hemorrhagic shock
32
33

34 Keywords: Hemorrhagic Shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic
35
36 receptor.
37
38
39
40
41
42

43 Corresponding Author:
44

45
46 Federico Aletti, PhD
47

48 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano
49

50 Piazza Leonardo da Vinci, 32 – 20133 – Milan, Italy.
51

52 E-mail address: federico.aletti@polimi.it
53

54 *These authors contributed equally to the work as co-first authors.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **ABSTRACT**
5
6

7 **BACKGROUND:** Irreversible hemorrhagic shock is characterized by hyporesponsiveness to
8 vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to
9 this phenomenon. Previous studies have shown that decreased intestinal perfusion in
10 hemorrhagic shock leads to proteolytically-mediated increases in gut permeability, with
11 subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is
12 achieved in part by α_1 receptor modulation, which may be affected by vasoactive factors; we thus
13 hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be
14 prevented by enteral protease inhibition. **METHODS:** Rats were exposed to experimental
15 hemorrhagic shock (35 mmHg mean arterial blood pressure for 2 hrs, followed by reperfusion
16 for 2 hrs) and challenged with phenylephrine (2 μ g/kg) at discrete intervals to measure
17 vasopressor responsiveness. A second group of animals received enteral injections with the
18 protease inhibitor tranexamic acid (TXA) (127 mM) along the small intestine and cecum one
19 hour following induction of hemorrhagic shock.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **RESULTS:** Blood pressure response (duration and amplitude) to phenylephrine after reperfusion
40 was significantly attenuated in animals subjected to hemorrhagic shock compared to baseline and
41 control non-shocked animals, and was restored to near baseline by enteral TXA. Arteries from
42 shocked animals also displayed decreased α_1 receptor density with restoration to baseline
43 following enteral TXA treatment. In vitro, rat shock plasma decreased α_1 receptor density in
44 smooth muscle cells, which was also abrogated by enteral TXA treatment.
45
46
47
48
49
50
51
52
53
54

55 **CONCLUSIONS:** Results from this study demonstrate that experimental hemorrhagic shock
56 leads to decreased response to the α_1 -selective agonist phenylephrine and decreased α_1 receptor
57 density via circulating shock factors. These changes are mitigated by enteral TXA with
58
59
60
61
62
63
64
65

1
2
3
4 correspondingly improved hemodynamics. Proteolytic inhibition in the lumen of the small
5
6 intestine improves hemodynamics in hemorrhagic shock, possibly by restoring α_1 adrenergic
7
8 functionality necessary to maintain systemic blood pressure and perfusion.
9

10
11
12 LEVEL OF EVIDENCE: N/A
13
14
15
16
17
18
19
20

21 **Acknowledgement:** Supported by NIH grant GM 85072, Career Development Award (CDA2)
22
23 1IK2BX001277-01A1 from the Department of Veterans Affairs, Veterans Health
24
25 Administration, Office of Research and Development, GM 85072, the “CelSys Shock” Marie
26
27 Curie International Outgoing Fellowship (PIOF-GA-2012-328796) of the European Union in
28
29 support of the corresponding author, and the “ShockOmics” Project of the European Union
30
31 (Grant#602706).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

BACKGROUND

One of the most challenging problems in the care of patients suffering from circulatory shock is vasopressor resistance, which is characterized by hyporesponsiveness to the infusion of vasoactive drugs required to maintain adequate hemodynamics. The mortality of patients in shock requiring vasopressors is high (> 50%) and hypotension characterizes the majority of deaths despite vasopressor support.¹⁻³

While the cause of hypotension that typically accompanies and characterizes circulatory shock can be attributed to vasodilation generated by the strong inflammatory response occurring in shock, no consensus exists as to the mechanisms for vasopressor hyporeactivity. Several hypotheses have been postulated to account for vasopressor resistance. For instance, it is known that systemic vasopressin levels are reduced in shock⁴ and that nitric oxide production may be increased and contributes to vasodilation and cardiac dysfunction.⁵ However, clinical trials have proposed therapies interfering with these pathways without success in reducing mortality to vasopressor resistance-induced refractory shock.^{6,7}

One potential mechanism contributing to hyporesponsiveness to vasopressor administration in hemorrhagic shock may be altered function of the vascular α_1 adrenergic receptor, a G_q -coupled receptor which is a fundamental controller of vascular tone and determinant of systemic vascular resistance (SVR). Activation of α_1 increases intracellular calcium and subsequent smooth muscle contraction resulting in vasoconstriction of the vasculature. Although the α_1 adrenergic receptor is also found in the heart, α_1 appears to be almost exclusively involved in the maintenance of vascular tone.^{8, 9} SVR and thus blood pressure, when exogenously supported in the critical care setting, are with the exception of

1
2
3
4
5 vasopressin, controlled by agents that act on the α_1 adrenergic receptor (phenylephrine,
6
7 epinephrine, norepinephrine, dopamine). Therefore, decreased responsiveness to this receptor
8
9
10 has important implications for available treatment options and outcome.

11
12
13 It has been previously shown that hemorrhagic shock may reduce the surface density of
14
15 important transmembrane receptors, such as the insulin receptor,¹⁰ thus reducing the response to
16
17 insulin (insulin resistance) in shock. We hypothesize that decreased transmembrane receptor
18
19 density in shock may result, either directly or indirectly, from uncontrolled proteolytic activity,
20
21 possibly by digestive pancreatic enzymes from the small intestine.¹¹ Integrity of the intestinal
22
23 mucous layer is compromised in circulatory shock,¹²⁻¹⁴ and a consequence of the breakdown of
24
25 this barrier may be leakage of digestive enzymes and inflammatory products from the intestinal
26
27 lumen into the bloodstream.¹⁵ Once in the systemic circulation, these mediators may lead to
28
29 remote organ failure and mortality (autodigestion).¹¹

30
31
32 The objective of this study was to investigate a new hypothesis for vasopressor resistance
33
34
35 in shock, by analyzing alterations in α_1 adrenergic receptor expression in a rat model of
36
37 hemorrhagic shock. We also tested a therapeutic intervention aimed at maintaining vasopressor
38
39 responsiveness in hemorrhagic shock, by the administration of tranexamic acid (TXA) in the
40
41 intestinal lumen. Used intravenously to decrease bleeding predominantly due to its actions as a
42
43 plasminogen inhibitor,¹⁶ TXA also can function as a trypsin inhibitor and has been shown to
44
45 improve outcomes in shock when given enterally,¹⁵ in part by protecting the gut mucosal barrier
46
47 from proteolytic degradation.^{17, 18}

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

METHODS

A. Experimental Protocol

All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego and conform to the Guide for the Care and Use of Laboratory Animals, 8th edition, by the National Institutes of Health (2011). Twenty-four non-fasted male Wistar rats (300-450 g, Harlan Laboratories, Inc., Indianapolis, IN) were randomly assigned to either Control (no shock) (n=6), hemorrhagic shock (HS) (n=6), hemorrhagic shock with enteral tranexamic acid treatment (HS + TXA) (n=6), or hemorrhagic shock with enteral Golytely® (HS + Vehicle) as a hemorrhagic shock control (n=6). All rats were anesthetized (xylazine, 4 mg/kg; ketamine 75 mg/kg IM) with supplemental anesthesia administered intravenously as needed (xylazine, 4 mg/kg; ketamine 7.5 mg/kg IV). The right femoral vein and artery were cannulated for blood withdrawal and intravenous supplemental anesthesia and continuous monitoring of arterial pressure, respectively. Body temperature was maintained at 37°C via water-heated support and heat blanket.

Control animals were monitored for 4 hours under anesthesia without other interventions. HS and HS + TXA animals were allowed 5 min for hemodynamic stabilization after induction of anesthesia and vascular line placement. All animals were heparinized (1 unit heparin/cc total blood volume, estimated at 6% body weight, intravenously) to allow for blood withdrawal. Hemorrhage was induced by blood withdrawal through the femoral vein (0.5 cc/min) to a target mean arterial blood pressure (MABP) of 35 mmHg. MABP was maintained between 30 and 40 mmHg for 2 hours, after which time the withdrawn blood was returned to the animals (0.5 cc/min). Maintenance of MABP during the ischemic period was accomplished by the removal or

1
2
3
4
5 return of small aliquots of blood as necessary to ensure maintenance of the targeted pressure. The
6
7 shed blood was maintained at room temperature (22°C) during hypovolemia, and warmed to
8
9 37°C prior to return to the animals. Animals were monitored for an additional two hours upon
10
11 completion of blood return.
12
13
14

15 To test for vascular responsiveness the selective α_1 adrenergic agonist phenylephrine (2
16
17 $\mu\text{g}/\text{kg}$) was administered as intravenous bolus (0.1 ml) once before hemorrhage to obtain
18
19 baseline response and again serially at 30 minutes, 90 minutes, and 120 minutes after the start of
20
21 reperfusion. Total deflection of MABP from baseline (ΔMABP), i.e. difference between
22
23 maximum value of MABP after challenge and value before challenge, as well as duration of
24
25 response (DOR) (time to return to within 3% of baseline) were measured as indices of vascular
26
27 response to phenylephrine. In addition, % changes in the area-under-the-curve (ΔAUC) from
28
29 baseline were calculated for all animals and all groups as another method for understanding and
30
31 interpreting the data.
32
33
34
35
36
37

38 In HS + TXA animals, tranexamic acid (127 mM TXA, Cyclokapron, Pfizer) was
39
40 administered at 1 hour into the hypovolemic period into the lumen of the small intestine via
41
42 sequential injections (BD Sub-Q 26G 5/8 PrecisionGlide Needle, Becton Dickinson & Co.)
43
44 spaced approximately 5 cm apart for an average of 8 injections longitudinally along its length.
45
46 GoLytely® (0.14 g /ml 0.9% sterile water) was used as carrier solution. A total fluid volume of
47
48 15 ml was injected into the lumen of the small intestine. An additional 2 ml of TXA in vehicle
49
50 was injected into the cecum. The dosage of the TXA was based on previously determined
51
52 effective concentrations.¹⁵ A second group of animals (HS + Vehicle) undergoing hemorrhagic
53
54 shock was instrumented as above and enteral injections of carrier solution only (GoLytely®)
55
56 were performed as an additional hemorrhagic shock control. Hemodynamics from this group
57
58
59
60
61
62
63
64
65

1
2
3
4
5 were indistinguishable from those of the HS group, and subsequent analyses were carried out on
6
7 the HS animals (**Figure 1**). HS, HS + TXA, and HS + Vehicle groups were subjected to
8
9 phenylephrine challenge (2 $\mu\text{g}/\text{kg}$) as described above once before hemorrhage and at 30, 90, and
10
11 120 min after the start of the reperfusion period.
12
13
14

15 Following a two-hour observation period after return of shed blood (Reperfusion),
16
17 animals were euthanized with B-Euthanasia (120 mg/kg). Death was confirmed by loss of signal
18
19 on blood pressure monitor followed by bilateral thoracotomy.
20
21
22
23
24
25

26 *B. Tissue Collection*

27
28

29 Renal arteries were harvested following laparotomy, gently rinsed to remove residual
30
31 blood and homogenized in lysis buffer (ThermoScientific). Homogenates were treated with the
32
33 addition of a protease inhibitor cocktail (1:25, Roche) for Western blot analysis. Arterial
34
35 homogenates were stored at -80°C for later use. Right femoral arteries were gently excised,
36
37 washed four times in 10% formalin for 15 min each, and placed directly into 10% formalin and
38
39 stored at room temperature for immunohistochemical analysis (IHC).
40
41
42
43
44
45
46
47

48 *C. Western Blot Detection of Arterial α_1 Adrenergic Receptor*

49
50

51 Renal artery homogenate samples from each animal (60 $\mu\text{l}/\text{sample}$; 0.5 $\mu\text{g}/\mu\text{l}$) were
52
53 separated by SDS-PAGE. For Western blotting, proteins were transferred to a 0.45 μm pore size
54
55 nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA; #162-0097). Following
56
57 blockade with 5% nonfat dry milk in buffer (Tris-Buffered Saline and Tween 20, TBST),
58
59
60
61
62
63
64
65

1
2
3
4
5 primary antibodies against α_{1D} adrenergic receptor (α_{1R}) (H-142, 1:300, sc-10721, Santa Cruz
6
7 Biotechnology, Santa Cruz, CA) were applied. β -actin (C4, 1:100, sc-47778, Santa Cruz
8
9 Biotechnology, Santa Cruz, CA) was used as loading control. Corresponding secondary
10
11 antibodies were applied at 1:5000 dilution. Antibodies were diluted in TBST. Supersignal West
12
13 Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA; #34096) was used
14
15 for imaging. Molecular weights were estimated by use of an electrophoresis marker (Sigma
16
17 Aldrich, C1992). Gels were digitized and bands were analyzed by densitometry in ImageJ, and
18
19 results are reported as ratios of α_{1R} / β -actin.
20
21
22
23
24
25
26
27

28 *D. Immunohistochemistry (IHC) Detection of Arterial α_1 Adrenergic Receptor*

29
30

31 Femoral arteries were resected, formalin fixed, and mounted longitudinally for
32
33 sectioning. 30 μ m sections were made along the length of the artery and placed in 10% formalin
34
35 overnight. Sections were rinsed in distilled water to remove residual formalin. Endogenous
36
37 peroxidase activity was removed with Bloxall (Vector Laboratories, Burlingame, CA, SP-6000).
38
39 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, S-2012) was then used as a
40
41 blocking reagent followed by primary antibody incubation with α_{1D} antibody (1:200, sc-10721,
42
43 Santa Cruz Biotechnology, Santa Cruz, CA) for 90 min. Sections were incubated for 30 min in
44
45 ImmPRESS anti-rabbit Ig (Vector Laboratories, Burlingame, CA, MP-7401) and ImmPACT
46
47 DAB (Vector Laboratories, Burlingame, CA, SK-4105) was used for staining. Sections were
48
49 mounted using Vectamount (Vector Laboratories, Burlingame, CA, H-5000). Bright-field
50
51 imaging was carried out at 10X objective magnification. Images were digitized to 8-bit format
52
53 and measurements were taken of smooth muscle regions in each section (6 measurements/image,
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 10 images/animal). All analysis was performed on ImageJ. Precautions were taken to assure that
6
7 all IHC steps were carried out under standard conditions to allow quantitative comparison with
8
9 digital image analysis.
10

11 12 13 14 15 16 *E. Immunocytochemistry of Smooth Muscle Cells Following Rat Plasma Incubation (ICC)* 17

18
19 Blood samples from Control (n = 6), HS (n = 6), HS + TXA (n = 6), and HS + Vehicle (n
20
21 = 6) rats were drawn and blood was centrifuged at 600g for 10 min to achieve plasma separation.
22
23 Human carotid smooth muscle cells (SMC) (HCtASMC; Cell Applications, San Diego, CA)
24
25 were cultured in growth medium (311D-250; Cell Applications, San Diego, CA) at 37 °C in an
26
27 atmosphere of 5% CO₂ and allowed to reach approximately 100% confluence before being
28
29 exposed to either starvation medium (310-500; Cell Applications, San Diego, CA), or plasma
30
31 from Control, HS, HS +TXA, or HS + Vehicle animals. SMCs were incubated in the presence of
32
33 plasma variant or starvation medium for 3 hours at 37°C. Cells were starved in serum free media
34
35 for 12 h prior to experimentation and plasma samples were diluted in a 1:5 ratio in starvation
36
37 medium immediately prior to incubation. Added plasma was normalized to volume rather than
38
39 protein content. Cells were stained as described above for rat femoral artery sections. Images
40
41 were acquired at 10X objective magnification, digitized to 8-bit format and measurements were
42
43 taken as the average intensity for individual cells. All analysis was performed on ImageJ.
44
45 Precautions were taken to assure that all ICC steps were carried out under standard conditions to
46
47 allow quantitative comparison with digital image analysis.
48
49
50
51
52
53
54
55
56
57
58

59 *F. Statistical Analysis* 60 61 62 63 64 65

1
2
3
4
5 Data are presented as mean \pm standard deviation (SD) unless otherwise noted. One-way
6
7 analysis of variance (ANOVA) was used where appropriate to evaluate the differences between
8
9 groups with a post-hoc Tukey correction. All analyses were performed using Graphpad
10
11 (Graphpad Software Inc., La Jolla, CA). A value of $p < 0.05$ was considered statistically
12
13 significant for all tests.
14
15
16
17
18

19 RESULTS

20 A. Blood Pressure Response to Enteral TXA Treatment

21
22
23 All groups subjected to HS were maintained at similar systemic blood pressures during
24
25 hypovolemia. After return of the shed blood, pressure was transiently restored, before dropping
26
27 significantly in the HS and HS + Vehicle groups (**Figure 1**). The animal group treated enterally
28
29 with TXA (HS + TXA) displayed significantly higher MABP after reperfusion compared to both
30
31 shock groups.
32
33
34
35
36
37
38
39
40
41

42 B. Systemic Vasopressor Response

43
44
45 Vasopressor responsiveness to phenylephrine challenge *in vivo* during hemorrhagic shock
46
47 was assessed by Δ MABP and DOR at baseline, and 30, 90 and 120 minutes after the start of
48
49 reperfusion (**Figure 2**). There were no significant differences between groups for either Δ MABP
50
51 or DOR at baseline. At 30 minutes after reperfusion there was a significant decrease in DOR for
52
53 the HS + Vehicle group ($p < 0.01$) and Δ MABP for both HS and HS + Vehicle groups compared
54
55 to baseline ($p < 0.01$, 0.0001, respectively) (**Figures 3 and 4**). This decrement in function in the
56
57 untreated HS groups continued for the duration of the experiment in both HS and HS + Vehicle
58
59
60
61
62
63
64
65

1
2
3
4
5 groups (90 min: Δ MABP ($p < 0.001$, 0.01 respectively), DOR ($p < 0.05$), and 120 min: Δ MABP
6
7 ($p < 0.05$, 0.01 respectively), and DOR ($p < 0.01$)). At no time point during the study did Δ MABP
8
9 or DOR in the HS + TXA group differ significantly from baseline. Differences in the changes in
10
11 the AUC (Δ AUC) from baseline (100%) showed a trend towards significance between the HS +
12
13 Vehicle (26%, $p = 0.05$) and HS groups (37%, $p = 0.064$) vs. HS + TXA (71% of baseline
14
15 response) at 90 minutes with significant differences between groups at 120 minutes: HS +
16
17 Vehicle (23%) and HS (26%) vs. HS + TXA (71%, $p < 0.01$ for both groups).
18
19
20
21
22
23
24

25 26 *C. α_1 Adrenergic Receptor Levels*

27
28
29 The α_1 adrenergic receptor was examined by Western blot to determine whether there
30
31 were changes in α_1 receptor density in shock and whether these levels were preserved after
32
33 treatment with enteral TXA. α_1 receptor density was markedly decreased ($p < 0.01$) by HS as
34
35 measured by Western blot (**Figure 5 A**) but maintained near Control levels by enteral treatment
36
37 with TXA. Measurements of α_1 receptor density were confirmed using IHC combined with
38
39 digital image analysis (**Figure 5 C**), where receptor levels as detected by immunolabeling were
40
41 also significantly decreased in HS compared to Control ($p < 0.01$). Enteral treatment with TXA
42
43 resulted in light absorbance levels similar to those of the Control group.
44
45
46
47
48
49
50
51

52 *D. Human Carotid SMC α_1 Adrenergic Receptor Levels*

53
54
55 SMCs were examined for α_1 using ICC (**Figure 6**). α_1 receptor density was significantly
56
57 decreased in HS and HS + Vehicle compared to Control groups ($p < 0.001$, $p < 0.05$,
58
59 respectively), while incubation with plasma from the HS + TXA group resulted in levels similar
60
61
62
63
64
65

1
2
3
4
5 to Control. α_1 receptor levels from the HS + Vehicle and HS groups did not differ significantly
6
7 from each other.
8
9

10 11 12 **DISCUSSION** 13

14
15 Fulminate decompensated hemorrhagic shock (Class IV),¹⁹ characterized by limited
16
17 responsiveness to fluid bolus and vasopressor therapy, carries a poor prognosis, in part because
18
19 no effective interventions exist. Lack of responsiveness to vasopressors and failure to maintain
20
21 vascular tone, commonly described in septic shock, are not well documented for hemorrhagic
22
23 shock, and although several hypotheses have been proposed, there currently exists no consensus
24
25 as to mechanism.²⁰ To study this problem, we examined the role of the α_1 adrenergic receptor in
26
27 experimental hemorrhagic shock. The α_1 receptor is the archetypical adrenergic receptor most
28
29 responsible for maintaining systemic vascular tone (vasoconstriction) and we hypothesized that
30
31 failure of this receptor, either through reduced density or function, results in decreased vascular
32
33 tone and subsequent hemodynamic collapse in hemorrhagic shock.⁸ Furthermore, we
34
35 hypothesized that enteral treatment with tranexamic acid (TXA), a mild trypsin inhibitor,²¹
36
37 would lead to improved hemodynamics in hemorrhagic shock, in part by maintaining α_1 receptor
38
39 activity by prevention of proteolytically-mediated processes. The mechanisms of action by which
40
41 enteral TXA is effective in experimental hemorrhagic shock appears unrelated to TXA's well-
42
43 known clinical role as an antifibrinolytic. Although IV TXA has some efficacy in hemorrhagic
44
45 shock,¹⁶ this has not been consistently reported.²² Other protease inhibitors with differing effects
46
47 on the coagulation system have also been found to be effective when given enterally to treat
48
49 experimental shock,^{23,24} and the limited patient information on the subject appears to support the
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 hypothesis that the protease inhibitors must be given enterally to display marked clinical
6
7 improvement.²⁵
8
9

10 This study confirms previous reports that enteral inhibition with TXA leads to improved
11
12 hemodynamics in experimental hemorrhagic shock.¹⁵ Using phenylephrine as a probe for α_1
13
14 adrenergic receptor responsiveness, we report here that systemic sensitivity to this receptor
15
16 decreases in experimental hemorrhagic shock with concomitant decrements in systemic pressure
17
18 maintenance. The decrease in hemodynamic response is manifest as measured by attenuated
19
20 changes in mean systemic blood pressure (Δ MABP) and in the duration of response (DOR) to
21
22 the pressor agent phenylephrine, as well as by changes in the total hemodynamic effectiveness of
23
24 phenylephrine (Δ AUC). This reduction in hemodynamic responsiveness begins early in the
25
26 reperfusion period and continues unabated through the end of the experiment. Western blot
27
28 analysis and IHC confirm decreased α_1 adrenergic receptor density in hemorrhagic shock; the
29
30 decrement in density appears to be a mechanism by which α_1 receptor-mediated
31
32 hyporesponsiveness is mediated. This result is consistent with reports from other investigators on
33
34 adrenergic function in shock, which appears to be predominantly related to changes in receptor
35
36 density rather than function.²⁶
37
38
39
40
41
42
43
44

45 The mechanisms by which vascular α_1 adrenergic receptor density is modulated in shock
46
47 are unknown, but results from our study demonstrate that circulating factors in the blood may be
48
49 operant. These circulating mediators may include digestive pancreatic proteases¹⁵ and products
50
51 of proteolysis that either directly,²⁷ or indirectly through vasoactive degradation products¹⁴ affect
52
53 receptor function, and thus vascular responsiveness. Supporting this hypothesis are our current
54
55 findings that enteral TXA restores receptor levels to baseline concentrations with commensurate
56
57 improvements in hemodynamics in experimental hemorrhagic shock by protecting the ischemic
58
59
60
61
62
63
64
65

1
2
3
4
5 small bowel from proteolytic degradation;^{11, 12, 15} this protection is not seen with intravenous
6
7 protease inhibitor treatment.²⁸
8
9

10 There are several limitations to this study. Among these is the lack of a detailed described
11 mechanism by which enteral TXA inhibition in the bowel restores α_1 receptor function
12 systemically. Previous studies have demonstrated increased survival after experimental shock
13 with enteral protease inhibition,¹⁵ but not with intravenous protease inhibition.^{28, 29} The reasons
14 for this are two-fold: first, the high concentrations of proteolytic enzymes in the bowel
15 (millimolar range) can only be overcome by high concentrations of inhibitor in the bowel lumen,
16 which is not feasible in the systemic circulation. Second, and more importantly, by limiting
17 proteolytic degradation of the bowel mucosa and resulting permeability changes,^{13, 17, 18, 30} enteral
18 protease inhibition prevents the systemic egress of non-protease gut mediators that might
19 otherwise affect α_1 receptor function and result in subsequent hypotension. Further studies are
20 necessary to identify the mediators and mechanisms responsible for this phenomenon. Likewise,
21 although changes in α_1 receptor responsiveness appear to be secondary to changes in density as
22 shown by Western blot and IHC analysis, the possibility of abnormal α_1 receptor binding or
23 malfunction in hemorrhagic shock cannot be excluded. Finally, it is acknowledged that other
24 receptors, both adrenergic (e.g., β_1 , β_2) and otherwise (e.g., vasopressin), are also operant and
25 may be affected in hemorrhagic shock; further studies are necessary to clarify the roles of these
26 receptors in this condition and the possible effect of enteral TXA in modulating them.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 In conclusion, this study proposes a possible mechanism for vasopressor resistance-
53 induced refractory shock by demonstrating that hemorrhagic shock decreases α_1 adrenergic
54 receptor responsiveness and density. Decrements in α_1 adrenergic receptor activity and
55 concentrations are mitigated by enteral treatment with TXA, with resultant improved
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 hemodynamics and vascular responsiveness. Restoration of α_1 receptor density and functionality
6
7 may be a key mechanism by which enteral TXA improves systemic blood pressure and survival
8
9
10 in experimental hemorrhagic shock.
11
12
13
14

15 **AUTHOR CONTRIBUTION STATEMENT**

16
17
18
19 MS, FA, JBL, AT, MC, and JL participated in data acquisition, analysis and experimental
20
21 design; FA, GWS and EBK participated in experimental design, data analysis, data interpretation
22
23 and drafting of the manuscript.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. *Crit Care Res Pract.* 2013;2013:654708
2. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. *The New England journal of medicine.* 2010;362:779-789
3. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F. Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. *Intensive Care Med.* 2010;36:2019-2029
4. Landry DW, Levin HR, Gallant EM, Ashton RC, Jr., Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation.* 1997;95:1122-1125
5. Thiemeermann C, Szabo C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. *Proceedings of the National Academy of Sciences of the United States of America.* 1993;90:267-271
6. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The triumph randomized controlled trial. *Jama.* 2007;297:1657-1666
7. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled,

- 1
2
3
4
5 double-blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in
6
7 patients with septic shock. *Critical care medicine*. 2004;32:21-30
8
- 9
10 8. Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: Basic
11
12 science and clinical implications. *Pharmacol Ther*. 2000;88:281-309
13
- 14
15 9. Thiele RH, Nemergut EC, Lynch C, 3rd. The clinical implications of isolated alpha(1)
16
17 adrenergic stimulation. *Anesth Analg*. 2011;113:297-304
18
- 19
20 10. DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage:
21
22 Mechanism for insulin resistance in the spontaneously hypertensive rat. *Hypertension*.
23
24 2008;52:415-423
25
- 26
27 11. Altshuler AE, Kistler EB, Schmid-Schonbein GW. Autodigestion: Proteolytic
28
29 degradation and multiple organ failure in shock. *Shock*. 2016;45:483-489
30
- 31
32 12. Kistler EB, Alsaigh T, Chang M, Schmid-Schonbein GW. Impaired small-bowel barrier
33
34 integrity in the presence of luminal pancreatic digestive enzymes leads to circulatory
35
36 shock. *Shock*. 2012;38:262-267
37
- 38
39 13. Chang M, Alsaigh T, Kistler EB, Schmid-Schonbein GW. Breakdown of mucin as barrier
40
41 to digestive enzymes in the ischemic rat small intestine. *PLoS One*. 2012;7:e40087
42
- 43
44 14. Alsaigh T, Chang M, Richter M, Mazor R, Kistler EB. In vivo analysis of intestinal
45
46 permeability following hemorrhagic shock. *World J Crit Care Med*. 2015;4:287-295
47
- 48
49 15. DeLano FA, Hoyt DB, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in
50
51 the intestine increases survival after experimental shock. *Sci Transl Med*.
52
53 2013;5:169ra111
54
- 55
56 16. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H,
57
58 Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H,
59
60
61
62
63
64
65

- 1
2
3
4
5 Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Oildashi
6
7 F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid
8
9 on death, vascular occlusive events, and blood transfusion in trauma patients with
10
11 significant haemorrhage (crash-2): A randomised, placebo-controlled trial. *Lancet*.
12
13 2010;376:23-32
14
15
16
17 17. Peng Z, Ban K, LeBlanc A, Kozar RA. Intraluminal tranexamic acid inhibits intestinal
18
19 sheddases and mitigates gut and lung injury and inflammation in a rodent model of
20
21 hemorrhagic shock. *J Trauma Acute Care Surg*. 2016;81:358-365
22
23
24 18. Diebel ME, Diebel LN, Manke CW, Liberati DM, Whittaker JR. Early tranexamic acid
25
26 administration: A protective effect on gut barrier function following ischemia/reperfusion
27
28 injury. *J Trauma Acute Care Surg*. 2015;79:1015-1022
29
30
31
32 19. Choi SB, Choi JY, Park JS, Kim DW. Atls hypovolemic shock classification by
33
34 prediction of blood loss in rats using regression models. *Shock*. 2016
35
36
37 20. Duan C, Yang G, Li T, Liu L. Advances in vascular hyporeactivity after shock: The
38
39 mechanisms and managements. *Shock*. 2015;44:524-534
40
41
42 21. Altshuler AE, Lamadrid I, Li D, Ma SR, Kurre L, Schmid-Schonbein GW, Penn AH.
43
44 Transmural intestinal wall permeability in severe ischemia after enteral protease
45
46 inhibition. *PLoS One*. 2014;9:e96655
47
48
49 22. Sondeen JL, Hanson MA, Prince MD, de Guzman R, Polykratis IA, Aden JK, 3rd, Cap
50
51 AP, Dubick MA. Double-blinded, placebo-controlled study of early tranexamic acid
52
53 treatment in swine uncontrolled hemorrhage model. *J Trauma Acute Care Surg*.
54
55 2016;80:81-88
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5 23. Doucet JJ, Hoyt DB, Coimbra R, Schmid-Schonbein GW, Junger WG, Paul LW, Loomis
6
7 WH, Hugli TE. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate
8
9 reduces neutrophil activation and transfusion requirements after hemorrhagic shock. *J*
10
11 *Trauma*. 2004;56:501-510; discussion 510-501
12
13
- 14 24. Fitzal F, DeLano FA, Young C, Rosario HS, Schmid-Schonbein GW. Pancreatic protease
15
16 inhibition during shock attenuates cell activation and peripheral inflammation. *J Vasc*
17
18 *Res*. 2002;39:320-329
19
20
- 21 25. Lee YT, Wei J, Chuang YC, Chang CY, Chen IC, Weng CF, Schmid-Schonbein GW.
22
23 Successful treatment with continuous enteral protease inhibitor in a patient with severe
24
25 septic shock. *Transplant Proc*. 2012;44:817-819
26
27
- 28 26. Mizumachi K, Yahagi M, Kawabata H, Tezuka S, Honda T, Okada K. Decreased beta-
29
30 adrenergic receptor density in rat myocardium during hemorrhagic shock. *J Anesth*.
31
32 1991;5:404-411
33
34
- 35 27. DeLano FA, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the small
36
37 intestine prevents insulin resistance in hemorrhagic shock. *Shock*. 2014;41:55-61
38
39
- 40 28. Kistler EB, Lefer AM, Hugli TE, Schmid-Schonbein GW. Plasma activation during
41
42 splanchnic arterial occlusion shock. *Shock*. 2000;14:30-34
43
44
- 45 29. Deitch EA, Shi HP, Lu Q, Feketeova E, Xu DZ. Serine proteases are involved in the
46
47 pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. *Shock*.
48
49 2003;19:452-456
50
51
- 52 30. Chang M, Kistler EB, Schmid-Schonbein GW. Disruption of the mucosal barrier during
53
54 gut ischemia allows entry of digestive enzymes into the intestinal wall. *Shock*.
55
56 2012;37:297-305
57
58
59
60
61
62
63
64
65

FIGURE LEGENDS

Figure 1

Mean arterial blood pressure (MABP) of Control, Hemorrhagic Shock (HS), Hemorrhagic Shock + Enteral Tranexamic Acid (HS + TXA), and Hemorrhagic Shock + Vehicle (HS + Vehicle) groups. MABP was decreased to a mean of 35 mmHg over several minutes by the serial withdrawal of small aliquots of blood (0.5 ml/min). Reperfusion was carried out in analogous fashion by slow reinfusion of shed blood (0.5 ml/min). ** $p < 0.01$ Control vs. HS + TXA and # $p < 0.0001$ HS, HS + Vehicle vs. HS + TXA and Control; # $p < 0.0001$ Control vs. HS, HS + Vehicle, HS + TXA during ischemia period as per experimental design. There were no statistical differences between HS and HS + Vehicle groups at any time points. Results shown as Mean \pm SD.

Figure 2

Representative hemodynamic response to phenylephrine challenge (Δ MABP) at 120 min after start of reperfusion for a single animal in each group.

Figure 3

(A) Average absolute change in MABP (Δ MABP) per group over time in response to phenylephrine challenge (Mean \pm SD). (B) Δ MABP response to phenylephrine challenge 30 min after start of reperfusion, (C) Δ MABP response to phenylephrine challenge 90 min after start of reperfusion, (D) Δ MABP response to phenylephrine challenge 120 min after start of reperfusion. * $p < 0.05$ Control vs. HS, ** $p < 0.01$ Control vs. HS, HS + Vehicle, *** $p < 0.001$ Control vs. HS, **** $p < 0.0001$ Control vs HS + Vehicle. Results plotted as Mean \pm SD.

Figure 4

(A) Average response duration to phenylephrine challenge (DOR) per group over time (Mean \pm SD). (B) DOR to phenylephrine challenge 30 min after start of reperfusion, (C) DOR to phenylephrine challenge 90 min after start of reperfusion, (D) DOR to phenylephrine challenge 120 min after start of reperfusion. * $p < 0.05$ Control vs. HS, HS + Vehicle, ** $p < 0.01$ Control vs. HS, HS + Vehicle. Results plotted as Mean \pm SD.

Figure 5

(A) α_{1D} renal artery band density by Western blot with representative α_{1D} renal artery band (α -1 AR). The average of the control band densities was used as a reference. β -actin is shown as a loading control for the same animals. (B) Histogram of the average relative band intensities per

1
2
3
4
5 group expressed as ratios of α_1R / β -actin (n=6 animals/group). *p < 0.05, HS vs. HS + TXA; **p
6 < 0.01, Control vs. HS. Results plotted as Mean \pm SD. (C) Representative femoral artery
7 sections labeled for α_{1D} . Insets indicate sample smooth muscle regions of interest (squared
8 boxes) both before and after 8-bit conversion. (D) Histogram of labeling density values in digital
9 units. Scale bar is = 100 microns. **p < 0.01 Control vs. HS, *p<0.05 HS + TXA vs all other
10 groups. Results plotted as Mean \pm SD.
11
12
13
14

15 **Figure 6**

16
17 (A) Human carotid SMCs labeled for α_{1D} adrenergic receptor following 3 hour incubation with
18 rat plasma, normalized with respect to added plasma volume. Histograms display labeling
19 density values in digital units. Scale bar is = 10 microns. *p<0.05 Control vs. HS + Vehicle,
20 ***p < 0.001 Control vs. HS, ***p<0.001 HS + TXA vs. HS + Vehicle, ****p<0.0001 HS +
21 TXA vs. HS. Results plotted as Mean \pm SD.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1




Figure 2




Figure 3







Figure 4







Figure 5







Figure 6

